GRI Bio Etf Forward View - Simple Regression
| GRI Etf | USD 2.54 -0.38 -13.01% |
The hype cycle around GRI Bio can be quantified and compared to historical sentiment baselines. This module uses that comparison to generate price predictions that reflect the sentiment component of market value.
In the current reporting cycle, GRI Bio reflects the 14-period RSI of 0, indicating compressed downside momentum. This extreme reading suggests selling pressure has dominated recent sessions and may be due for at least a temporary pause.Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Current Year -15.37 | EPS Estimate Next Year -8.03 | Wall Street Target Price 159.9999 | EPS Estimate Current Quarter -1.11 |
This view relates GRI Bio's headline activity to recent price response context.
The Simple Regression forecasted value of GRI Bio on the next trading day is projected to be 0.38 with a mean absolute deviation of 0.99 and the sum of the absolute errors of 60.35.GRI Bio after-hype prediction price | $ 2.36 |
The sentiment view is a companion to forecasting, technical studies, analyst estimates, and earnings trends.
Cross-verify projections for GRI Bio using Historical Fundamental Analysis of GRI Bio. The view supplies historical context for the projection discussion.GRI Bio Additional Predictive Modules
Most predictive techniques to examine GRI price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for GRI using various technical indicators. When you analyze GRI charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Regression Price Forecast For the 16th of March 2026
Given 90 days horizon, the Simple Regression forecasted value of GRI Bio on the next trading day is expected to be 0.38 with a mean absolute deviation of 0.99 , mean absolute percentage error of 1.58 , and the sum of the absolute errors of 60.35 .Please note that although there have been many attempts to predict GRI Etf prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that GRI Bio's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Etf Forecast Pattern
| Backtest GRI Bio | GRI Bio Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for GRI Bio uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of GRI Bio etf data series using in forecasting. Note that when a statistical model is used to represent GRI Bio etf, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 118.5664 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.9894 |
| MAPE | Mean absolute percentage error | 0.29 |
| SAE | Sum of the absolute errors | 60.3542 |
Experienced GRI Bio's investors use mean reversion as a complement to momentum analysis: momentum identifies the trend; mean reversion identifies when that trend has extended beyond sustainable levels.
After-Hype Price Density Analysis
This probability distribution for GRI Bio is built from Monte Carlo simulations that incorporate GRI Bio's historical volatility, mean reversion tendencies, and jump risk. The resulting distribution captures a broader range of GRI Bio outcomes than simple linear.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The boundaries derived from GRI Bio's historical news analysis represent the range within which GRI Bio's price has typically settled after comparable headline events. GRI Bio's after-hype downside and upside margins for the prediction period are 0.12 and 10.61, respectively. Outcomes outside these boundaries are less common but not rare for GRI Bio.
Current Value
The after-hype framework applied to GRI Bio assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a ETF such as GRI Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading GRI Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Etf price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with GRI Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
2.28 | 8.25 | 0.18 | 0.24 | 4 Events | 6 Events | In 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
2.54 | 2.36 | 7.09 |
|
Hype Timeline
On the 15th of March 2026 GRI Bio is traded for 2.54. The ETF has historical hype elasticity of -0.18, and average elasticity to hype of competition of -0.24. GRI is projected to decline in value after the next headline, with the price expected to drop to 2.36. The average volatility of media hype impact on the ETF price is over 100%. The price depreciation on the next news is expected to be -7.09%, whereas the daily expected return is currently at -2.28%. The volatility of related hype on GRI Bio is about 7932.69%, with the expected price after the next announcement by competition of 2.30. The ETF has price-to-book (P/B) ratio of 0.61. Some equities with similar Price to Book (P/B) outperform the market in the long run. GRI Bio recorded a loss per share of 121.8. The ETF completed a 1:28 stock split on 26th of January 2026. Considering the 90-day investment horizon the next projected press release will be in 4 days. Cross-verify projections for GRI Bio using Historical Fundamental Analysis of GRI Bio. The view supplies historical context for the projection discussion.Related Hype Analysis
Understanding GRI Bio's position within its competitive set helps investors assess whether news affecting a peer is a headwind or tailwind for GRI Bio. This distinction requires knowledge of the competitive dynamics specific to GRI Bio's industry.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| CNSP | CNS Pharmaceuticals | -0.12 | 7 per month | 0.00 | -0.26 | 7.22 | -11.64 | 31.54 | |
| JAGX | Jaguar Animal Health | -0.05 | 9 per month | 0.00 | -0.02 | 15.87 | -16.95 | 125.57 | |
| SILO | Silo Pharma | -0.06 | 20 per month | 0.00 | -0.06 | 7.14 | -9.68 | 30.71 | |
| BDRX | Biodexa Pharmaceticals | 0.01 | 8 per month | 0.00 | -0.19 | 8.37 | -16.00 | 89.71 | |
| ABP | Abpro Holdings | -0.36 | 7 per month | 16.63 | 0.06 | 11.95 | -34.65 | 917.97 | |
| INM | InMed Pharmaceuticals | -0.02 | 6 per month | 0.00 | -0.11 | 7.48 | -9.09 | 30.23 | |
| CANF | Can Fite Biopharma | 0.08 | 7 per month | 0.00 | -0.07 | 10.00 | -10.33 | 43.99 | |
| SXTP | 60 Degrees Pharmaceuticals | -0.42 | 9 per month | 8.34 | 0.04 | 10.44 | -17.62 | 174.37 | |
| GNPX | Genprex | -0.11 | 24 per month | 0.00 | -0.06 | 14.98 | -10.89 | 36.99 | |
| CLDI | Calidi Biotherapeutics | 0.01 | 7 per month | 0.00 | -0.25 | 4.80 | -7.32 | 61.47 |
Other Forecasting Options for GRI Bio
Understanding GRI Bio's price movement is a prerequisite for any investor considering GRI as a position. GRI Etf price charts are frequently cluttered with noise that can interfere with accurate interpretation.GRI Bio Related Equities
The following equities are related to GRI Bio within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing GRI Bio against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
GRI Bio Market Strength Events
For traders and investors in GRI Bio, market strength indicators offer a quantitative framework for evaluating the etf's responsiveness to market conditions. These tools help identify when trading GRI Bio shares is most likely to generate favorable returns.
GRI Bio Risk Indicators
Analyzing GRI Bio's risk indicators provides a critical input for price forecasting and investment risk management. By quantifying the risk in GRI Bio's investment, investors can make more informed decisions about their exposure and hedging strategies.
| Mean Deviation | 7.44 | |||
| Standard Deviation | 10.54 | |||
| Variance | 111.11 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for GRI Bio
Coverage intensity for GRI Bio matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
GRI Bio Short Properties
Short sentiment tied to GRI Bio matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 98.2 K | |
| Cash And Short Term Investments | 8.2 M |
More Resources for GRI Etf Analysis
Other Information on Investing in GRI Etf
Financial ratios for GRI Bio provide valuation context across profits, cash flow, and enterprise value. They help compare GRI across valuation measures and peers.